Summit Therapeutics Announces Promising Phase III Trial Results for Ivonescimab in Lung Cancer
First-line treatment shows significant improvement in progression-free survival over pembrolizumab, marking a potential shift in NSCLC care Summit Therapeutics (SMMT) ...


















